+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Gastro-oesophageal reflux symptoms--clinical findings and effect of ranitidine treatment

Gastro-oesophageal reflux symptoms--clinical findings and effect of ranitidine treatment

European Journal of Surgery. Supplement. 1998(583): 6-13

This study was performed to study the demography, effect of treatment with ranitidine and relapse pattern in patients with reflux symptoms. Patients with reflux symptoms were examined by endoscopy and included in a double-blind, comparative trial of placebo and ranitidine 150 mg b.i.d. for two weeks. At two weeks satisfied patients continued the same treatment. Non-satisfied patients were randomised to ranitidine 150 mg b.i.d. or q.i.d for another two weeks. After four weeks medication was stopped and satisfied patients were followed for 24 weeks. No further endoscopy was performed. Four hundred and twenty-seven patients were randomised. At two weeks there was no significant difference between placebo and ranitidine, regarding the proportion of patients with complete relief from symptoms or satisfied with treatment. Ranitidine was superior to placebo in improving symptoms at two weeks. Ranitidine, 150 mg q.i.d. offered no additional advantage in weeks three to four over prolonging treatment with 150 mg b.i.d. after the first two weeks. Patients with oesophagitis at inclusion relapsed more than those with symptoms only, 67% compared with 52%, (p = 0.013). The effect of ranitidine was marginal compared to placebo. The relapse rate was high after treatment stopped.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 046149727

Download citation: RISBibTeXText

PMID: 10027666

Related references

Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes. International Journal of Clinical Practice 60(3): 275-283, 2006

On-demand treatment of gastro-oesophageal reflux symptoms: a comparison of ranitidine 75 mg with cimetidine 200 mg or placebo. Alimentary Pharmacology and Therapeutics 12(9): 909-917, 1998

Are frequent short gastro-oesophageal reflux episodes the cause of symptoms in patients with non-ulcer dyspepsia responding to treatment with ranitidine?. Scandinavian Journal Of Gastroenterology. 30(9): 829-832, 1995

The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Alimentary Pharmacology and Therapeutics 16(9): 1655-1662, 2002

Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Alimentary Pharmacology and Therapeutics 16(5): 899-907, 2002

Ranitidine effervescent and famotidine wafer in the relief of episodic symptoms of gastro-oesophageal reflux disease. Scandinavian Journal of Gastroenterology 32(6): 513-518, 1997

A dose-ranging study of ranitidine and its effect on intragastric and intra-oesophageal acidity in subjects with gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics. 8(4): 443-451, 1994

Comparative investigation of the effects of lansoprazole and ranitidine on the histological findings of gastro-oesophageal reflux disease. Leber Magen Darm 28(1): 24-28, 1998

Effect of atropine on gastro-oesophageal reflux and transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease. Gut 43(1): 12-16, 1998

Pantoprazole effectively controls intra-oesophageal pH and promotes oesophageal healing: Further evidence for ranitidine-induced tolerance in patients with gastro-oesophageal reflux disease. Clinical Drug Investigation 21(4): 265-272, 2001

Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Italian Journal of Gastroenterology and Hepatology 30(1): 19-27, 1998

CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: Variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Alimentary Pharmacology and Therapeutics 17(12): 1521-1528, 15th June, 2003

Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics 21(Suppl. 2): 2-9, 2005